Madrigal Pharmaceuticals (MDGL) Accumulated Expenses (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of Accumulated Expenses data on file, last reported at $275.8 million in Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 122.09% year-over-year to $275.8 million in Q1 2026; TTM through Mar 2026 was $275.8 million, a 122.09% increase from a year earlier, with the FY2025 full-year figure at $260.4 million, up 108.82% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $275.8 million, up from $260.4 million in the prior quarter.
• Over the last five years, Accumulated Expenses for MDGL reached as high as $345.4 million in Q3 2025 and fell as low as $53.4 million in Q1 2022.
• Historically, Accumulated Expenses has averaged $133.1 million across 5 years, with a median of $92.3 million in 2024.
• Across the five-year window, Accumulated Expenses retreated 1.62% in 2023 and jumped 163.64% in 2025, its largest moves.
• Year by year, Accumulated Expenses stood at $91.5 million in 2022, then declined by 1.62% to $90.0 million in 2023, then soared by 38.58% to $124.7 million in 2024, then surged by 108.82% to $260.4 million in 2025, then climbed by 5.9% to $275.8 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $275.8 million in Q1 2026, $260.4 million in Q4 2025, and $345.4 million in Q3 2025.